{"id":"W2036186700","doi":"10.1136/gut.2005.089854","title":"Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial","year":2006,"lang":"en","type":"article","venue":"Gut","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":146,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; McGill University; University of British Columbia; Vancouver General Hospital; Western University","funders":"Generalitat Valenciana","keywords":"Daclizumab; Monoclonal antibody; Medicine; Ulcerative colitis; Placebo; Double blind; Monoclonal; Vedolizumab; Receptor; Internal medicine; Pharmacology; Immunology; Gastroenterology; Antibody; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002277077,0.0008124859,0.001791904,0.0004214001,0.000361242,0.0006063062,0.0006245351,0.001730002,0.004815167],"category_scores_gemma":[0.001726957,0.0003884923,0.001337546,0.0003941029,0.0009352749,0.0004516967,0.0002182652,0.001625878,0.0006168384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004743265,"about_ca_system_score_gemma":0.0008023958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005174302,"about_ca_topic_score_gemma":0.0009987259,"domain_scores_codex":[0.9993469,0.000386072,0.00006229692,0.00008181734,0.00006233589,0.00006052351],"domain_scores_gemma":[0.9990699,0.0003909983,0.0002214585,0.00004126322,0.00005716704,0.0002192975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9646785,0.004397545,0.0005852869,0.00145229,0.0007140776,0.00005393075,0.00004537507,0.0001909489,0.006100121,0.00007870112,0.0005872071,0.02111614],"study_design_scores_gemma":[0.9503595,0.04677668,0.001320399,0.00004573859,0.0003419273,0.00003169183,0.000005714879,0.0001207799,0.0004091579,0.00003081645,0.0005518798,0.000005639116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9689734,0.02262124,0.0008201877,0.0008221864,0.0006964847,0.003723562,0.0005776187,0.00008347926,0.001681861],"genre_scores_gemma":[0.9783423,0.01125025,0.001707753,0.001201482,0.0007732856,0.003737162,0.000753166,0.00001312804,0.002221514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004815167,"threshold_uncertainty_score":0.01610833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02153205195749857,"score_gpt":0.3038684070177876,"score_spread":0.282336355060289,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}